(Q38533619)

3 September 2017

1 reference

title

Hepatitis C virus drug resistance-associated substitutions: State of the art summary (English)

1 reference

3 September 2017

1 reference

1 reference

10

Tami Pilot-Matias

1 reference

3 September 2017

Erik Lontok

1

1 reference

3 September 2017

Patrick Harrington

2

1 reference

3 September 2017

Anita Howe

3

1 reference

3 September 2017

Tara Kieffer

4

1 reference

3 September 2017

Johan Lennerstrand

5

1 reference

3 September 2017

Oliver Lenz

6

1 reference

3 September 2017

Fiona McPhee

7

1 reference

3 September 2017

Hongmei Mo

8

1 reference

3 September 2017

Neil Parkin

9

1 reference

3 September 2017

Veronica Miller

11

1 reference

3 September 2017

language of work or name

English

0 references

publication date

10 June 2015

1 reference

3 September 2017

1 reference

3 September 2017

volume

62

1 reference

3 September 2017

issue

5

1 reference

3 September 2017

page(s)

1623-1632

1 reference

Curing chronic hepatitis C--the arc of a medical triumph

3 September 2017

cites work

1 reference

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

21 January 2018

1 reference

Nucleotide sequence and mutation rate of the H strain of hepatitis C virus

21 January 2018

1 reference

Accelerating drug development through collaboration: the Hepatitis C Drug Development Advisory Group

21 January 2018

1 reference

NS5A inhibitors in the treatment of hepatitis C.

21 January 2018

1 reference

New therapeutic strategies in HCV: polymerase inhibitors

21 January 2018

1 reference

Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system

21 January 2018

1 reference

Antiviral activity and resistance of HCV NS5A replication complex inhibitors

21 January 2018

1 reference

Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients

21 January 2018

1 reference

Sequence and phenotypic analysis for resistance monitoring in hepatitis C virus drug development: recommendations from the HCV DRAG.

21 January 2018

1 reference

Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034.

21 January 2018

1 reference

Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials

21 January 2018

1 reference

In vitro phenotypic characterization of hepatitis C virus NS3 protease variants observed in clinical studies of telaprevir

21 January 2018

1 reference

In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.

21 January 2018

1 reference

MK-7009, a Potent and Selective Inhibitor of Hepatitis C Virus NS3/4A Protease

21 January 2018

1 reference

Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus

21 January 2018

1 reference

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

21 January 2018

1 reference

Exploratory study of oral combination antiviral therapy for hepatitis C.

21 January 2018

1 reference

Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir

21 January 2018

1 reference

Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase

21 January 2018

1 reference

The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease Inhibitors

21 January 2018

1 reference

HCV direct-acting antiviral agents: the best interferon-free combinations

21 January 2018

1 reference

Resistance to direct antiviral agents in patients with hepatitis C virus infection

21 January 2018

1 reference

New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives

21 January 2018

1 reference

Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials

21 January 2018

1 reference

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial

21 January 2018

1 reference

Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial

21 January 2018

1 reference

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

21 January 2018

1 reference

All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study

21 January 2018

1 reference

Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders

21 January 2018

1 reference

Preliminary study of two antiviral agents for hepatitis C genotype 1.

21 January 2018

1 reference

Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection

21 January 2018

1 reference

Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C.

21 January 2018

1 reference

ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis

21 January 2018

1 reference

Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin

21 January 2018

1 reference

Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin

21 January 2018

1 reference

Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment-experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: a population and clonal analysis

21 January 2018

1 reference

Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics

21 January 2018

1 reference

Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors.

21 January 2018

1 reference

Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication

21 January 2018

1 reference

Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations.

21 January 2018

1 reference

All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study

21 January 2018

1 reference

A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C.

21 January 2018

1 reference

Characterization of Hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885.

21 January 2018

1 reference

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

21 January 2018

1 reference

Polymerase structures and function: variations on a theme?

21 January 2018

1 reference

Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.

21 January 2018

1 reference

Sofosbuvir and ribavirin in HCV genotypes 2 and 3.

21 January 2018

1 reference

Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials.

21 January 2018

1 reference

Randomized, placebo-controlled, single-ascending-dose study of BMS-791325, a hepatitis C virus (HCV) NS5B polymerase inhibitor, in HCV genotype 1 infection

21 January 2018

1 reference

Antiviral resistance and the future landscape of hepatitis C virus infection therapy

21 January 2018

1 reference

Update on hepatitis C virus resistance to direct-acting antiviral agents

21 January 2018

1 reference

JSH Guidelines for the Management of Hepatitis C Virus Infection: A 2014 Update for Genotype 1.

21 January 2018

1 reference

Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase

21 January 2018

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/HEP.27934

1 reference

3 September 2017

1 reference